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Methods
The concentrations of total Hcy, folate, and vitamin B12 were measured in serum
samples from 424 cognitively normal controls, 382 mild cognitive impairment
patients, and 56 dementia patients from Ansan Geriatric cohort. The Consortium
to Establish a Registry for Alzheimer’s Disease (CERAD) neuropsychological
battery was used to evaluate cognitive functions.
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Objectives
We aimed to determine whether serum levels of homocysteine (Hcy) and its
biological determinants, folate and vitamin B12, are related to cognitive decline
Thedementia patients had higher serumHcy (dementia, 17.6 6.9 mmol/L; control,
12.9 5.0 mmol/L; p< 0.001) and lower serum folate (dementia, 7.9 4.8 ng/mL;
control, 10.0 7.1 ng/mL; pZ 0.034) levels compared with controls. There was an
inverse relationship between Hcy levels and serum folate or vitamin B12 concentra-
tions. The cognitive status asmeasured by the (CERAD) scorewas inversely related to
Hcy levels. The adjusted odds ratio of dementia was 5.18 (95% confidence interval:
1.91e14.10; pZ 0.001) for moderate (30 Hcy> 15) hyperhomocysteinemia
compared with normal Hcy levels (15 mmol/L). In addition, there was weak asso-
ciation between low serum folate (<3.0 ng/mL) and the risk for dementia (crude
odds ratioZ 3.68; 95% confidence interval: 1.07e12.69; pZ 0.039).
Conclusion
Elevated serum Hcy and decreased serum folate concentrations are associated
with the risk of dementia in Korean elders.Diseases, Department of Biomedical Sciences, Korea National Institute of Health, Tongil-ro,
ear@gmail.com
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is properly cited.
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18 J.H. Song et al1. Introduction Therefore, hyperhomocysteinemia and deficiencies inMemory loss, dementia, and Alzheimer’s disease (AD)
are major public health concerns worldwide, especially
with the rapid increase in life expectancy in recent years.
Late-life dementia is characterized by a progressive loss
of memory and intellectual ability, also known as
cognitive function. With the goal of finding effective
strategies for prevention and treatment of cognitive
impairment with aging, many researchers are now
focusing on finding risk factors and biochemical
markers that are associated with late-life dementia.
Folate, vitamin B12, and homocysteine (Hcy) are
involved in one-carbon transfer reactions essential for the
maintenance of normal metabolic functions in the brain.
Hcy is derived from the essential amino acid methionine
through demethylation and can be remethylated to
methionine. Its metabolism depends on the B vitamins
cobalamin (vitamin B12), pyridoxine (vitamin B6), and
folic acid (vitamin B9).
1 Low levels of these vitamins,
mutations of the 5,10-methylenetetrahydrofolate reduc-
tase gene, and renal function deficiency are associated
with increased homocysteinemia.2 High Hcy suppresses
cellular levels of S-adenosylmethionine and S-adeno-
sylhomocysteine, interrupting the methylation of some
functional proteins and genes. The mechanism of how
hyperhomocysteinemia causes its neurotoxic effects is
not fully understood.3
Hcy has been identified as a peripheral marker directly
relevant to oxidative stress that reflects neuropathy and
vascular dysfunction.4,5 Epidemiology and clinical
studies have demonstrated a positive correlation between
elevated blood Hcy and the occurrences of dementia and
AD; thus, hyperhomocysteinemia has been proposed to be
a strong and independent risk factor for dementia.6e8
Other studies, however, have found no association
between plasma Hcy levels and AD.9 Hyper-
homocysteinemia has been identified in other neurolog-
ical disorders, including Parkinson’s disease10 and brain
atrophy.11
Folate is required in the synthesis of S-adenosylme-
thionine, a methyl donor for many important brain
biomolecules such as phospholipids, guanidinoacetate,
neurotransmitters, amino acids, and nucleic acids.1
Among other B vitamins, folate has received much
attention recently because its low serum level is found to
be closely associated with structural and functional
abnormalities in the brain. Low serum folate levels have
been related to atrophy of the cerebral cortex,12
dementia,13 and cerebrovascular diseases.14
Hcy accumulates in folate- and vitamin B12-deficient
patients. Reductions in Hcy levels can be achieved with
high doses of folic acid, vitaminB12, and vitaminB6 in the
general population15 and in individuals with AD.16
Supplementation with folate has resulted in a positive
effect on cognitive functions and memory deficits.17,18folate and vitamin B12 may contribute to the pathogenesis
of cognitive impairment. However, a recent clinical trial
reported that the regimen of high-dose B vitamin
supplements was effective in reducing Hcy but did not
slow cognitive decline in individuals with mild to
moderate AD.19 Thus, it is important to reveal whether
there are relationships between cognition function, levels
of Hcy, folate, and vitamin B12, and dementia, because
they could plausibly represent a disease-modifying
intervention in dementia.
In the present study, we analysed serum samples of
862 participants from Ansan Geriatric cohort to deter-
mine whether serum levels of Hcy, folate, and vitamin
B12 are related to cognitive functioning and the risk for
dementia.
2. Material and Methods
Participants aged 60 years or older were enrolled in the
Ansan Geriatric cohort study at the Geriatric Health
Clinic and Research Institute, Korea University Medical
Center, Ansan City, South Korea. A total of 862
participants were recruited from April 2006 to January
2008 and were evaluated by clinical and neuro-
psychological examinations after full medical history
and physical assessments.20
Written informed consent was obtained from all
subjects after the nature of the study and its procedures
had been explained. The research protocols were
reviewed and approved by the institutional review
boards of the Korea Centers for Disease Control and
Prevention and the Medical College of Korea
University.
Cognitive functioning and memory impairments of
subjects were assessed using a Korean version of the
Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) neuropsychological battery,21 which
included the following tests: Word Fluency Test for
animal categories, the 15-item Korean version of the
Boston Naming Test, the Korean version of the mini-
mental state examination (MMSE), Word List Memory
test, Constructional Praxis test, Word Delayed Recall,
Word Recognition, and Construction Recall. The total
CERAD score was used as an index for the overall
cognition level of the participants.22 All participants
were clinically evaluated according to published
guidelines, and each dementia patient met the criteria for
the Diagnostic and Statistical Manual of Mental Disor-
ders, fourth edition.23 Mild cognitive impairment (MCI)
was diagnosed based on the Mayo Clinic criteria.24
Blood samples were collected in serum separator tube
II and incubated for 30e45 minutes at room temperature
to allow clotting. The serum was then separated by
centrifugation, kept in a refrigerator (4C), and analysed
within 1 day. Serum Hcy concentrations were measured
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iluminescence method (ADVIA Centaur immunoassay
system, Bayer Healthcare, Tarrytown, NY, USA).25
Serum folate and vitamin B12 concentrations were
determined by competitive binding assays using a Simul
TRAC-SNB radioimmunoassay kit (ICN Biomedicals,
Ausora, Ohio, USA).
Statistical analysis of the mean values of different
variables from AD, MCI, and control groups was per-
formed by analysis of covariance using a general linear
model. A c2 test was used to compare the frequencies of
ApoE4 carriers and male:female ratios among AD, MCI,
and control groups. Associations between CERAD
scores and Hcy, folate, and vitamin B12 serum levels
were evaluated using Pearson’s correlation analysis.
Because age, gender, and duration of education were
significantly different in dementia and controls, these
variables were adjusted. Multivariable-adjusted logistic
regression analysis was conducted to examine the odds
ratio (OR) for dementia across the range of Hcy and
folate levels. Covariate variables were age, gender, and
duration of education, which were potential confounding
factors for cognitive function. Statistical significance
was considered at p< 0.05. SAS software release 9.1
(SAS Institute Inc., Cary, NC, USA) was used for the
statistical analysis.
3. Results
Demographic characteristics of the study subjects are
shown in Table 1. Of the 862 elderly Koreans examined,
382 (44.3%) had MCI and 56 (6.5%) were dementia
patients. The dementia patients were older and less
educated than the controls. There was a significant
difference in the male:female ratio among the three
diagnostic groups. The average age of the total partici-
pants was 71.1 5.2 years, and 56.0% of them were
female. Serum folate, vitamin B12, and Hcy levels were
measured in all 862 subjects. Apolipoprotein E (ApoE)Table 1 Characteristics of the study subjects
Characteristics Control
N 424
Age (yr) 69.4 4.5
Male (%) 53
Education (yr) 10.1 4.4
Homocysteine (mmol/L) 13.0 5.1
Folate (ng/mL) 10.0 7.2
Vitamin B12 (pg/mL) 713.0 313.4
ApoE4-allele positive (%) 16.5
MMSE score 27.4 2.3
CERAD score 69.8 8.6
Values are mean SD. The p values were calculated using analysis of covari
MCIZmild cognitive impairment; MMSEZmini-mental state examination;
SDZ standard deviation.genotype data were available for 807 (93.6%) partici-
pants, and the CERAD score was available for 805
(93.4%).
We found significantly increasedHcy (17.6 6.9 mmol/
L) serum concentrations in dementia patients compared
with healthy controls (13.0 5.1 mmol/L, p< 0.001) or
MCI patients (13.3 4.8 mmol/L, p< 0.001) and no
significant difference between MCI and controls
(pZ 0.375). The differences remained significant after
adjusting for age, gender, and duration of education.
The serum folate and vitamin B12 levels were
significantly lower in dementia patients compared
with controls with adjusted p values of 0.05 for folate
and 0.01 for vitamin B12. The folate and vitamin B12
levels of the MCI group were lower than those of the
controls and were without statistical significance.
However, vitamin B12 levels of dementia patients were
significantly lower than those of the MCI group
(p< 0.001).
Mean MMSE and CERAD scores were highest in
controls and lowest in dementia patients. Serum levels
of Hcy were inversely correlated with the CERAD score
(rZ0.183; p< 0.001), and folate levels were posi-
tively correlated with CERAD score (rZ 0.136;
p< 0.001) (Figure 1). Multiple regression analysis after
adjustment for age and gender showed that serum levels
of vitamin B12 and folate are associated with CERAD as
well as MMSE scores (p< 0.01). There was an inverse
correlation between serum Hcy and folate levels
(rZ0.227, p< 0.001, adjusted for age, gender, and
education).
None of the subjects in this study had severe hyper-
homocysteinemia (Hcy> 100 mmol/L); therefore, the
subjects were classified into three groups according to
serum Hcy concentrations: intermediate (>30 mmol/L),
moderate (30Hyt> 15), and normal (15) hyper-
homocysteinemias.26 The folate levels were categorized
as low (<3.0 ng/mL), normal (3.0 folate< 17.0), and
high (17.0) groups27 as shown in Table 2.MCI Dementia p value
382 56
72.6 5.1 74.6 5.6 <0.001
37 18 <0.001
5.1 4.3 2.5 3.7 <0.001
13.3 4.8 17.6 6.9 <0.001
8.9 6.1 7.9 4.8 0.010
705.2 295.4 586.4 237.7 0.012
17.3 20.4 0.765
25.1 3.0 16.3 5.4 <0.001
55.4 10.1 33.2 10.7 <0.001
ance or c2 test (male/female, ApoE4 allele). Bold values are p< 0.05.
CERADZConsortium to Establish a Registry for Alzheimer’s Disease;
Figure 1 Correlation between CERAD score and Hcy or folate concentrations. CERADZ Consortium to Establish a Registry for
Alzheimer’s Disease; HcyZ homocysteine.
20 J.H. Song et alA total of 192 subjects (22.3%) had moderate and 17
(1.9%) had intermediate hyperhomocysteinemia. The
group of subjects with hyperhomocysteinemia consisted
of a higher percentage of males, were older, had lower
levels of folate and vitamin B12, and had a higher
prevalence of dementia (p< 0.001) but not of MCI.
Only about 3% (26 subjects) had low folate levels but
had higher prevalence of dementia and MCI. Because
depression is frequently accompanied by cognitive
impairment in elders, we accessed the depressive
symptoms of the study participants using a Korean
version of the 30-item Geriatric Depression Scale. The
presence of depressive symptoms did not affect serum
Hcy, folate, or vitamin B12 concentrations in our study
subjects.
To assess the risk of dementia according to serum
Hcy and folate concentrations, multivariable logistic
regression analysis was performed. Because age, gender,
duration of education, and levels of Hcy, folate, vitamin
B12 were significantly different in dementia and
controls, these variables were included as covariates
(Table 3). Moderate hyperhomocysteinemia (30 mmol/
LHyt> 15 mmol/L) showed an increased risk forTable 2 Characteristics of the study subjects according to seru
Variables
Homocysteine (mmol/L)
Hcy 15 15<Hcy 30 30<Hcy
N 653 192 17
Age 70.6 4.9 72.8 5.6 73.8 5.2 <0
Male/female 247/406 120/72 12/5 <0
Education 7.4 5.1 7.5 5.1 8.1 5.5 0
Folate 10.3 6.9 6.6 4.2 4.5 3.9 <0
Vitamin B12 738.0 299.8 599.2 283.1 446.4 226.7 <0
Hcy 11.3 2.1 18.5 3.1 37.7 8.1 <0
MCI 297 79 6 0
Dementia 24 28 4 <0
CERAD score 62.5 13.0 57.0 15.7 55.3 16.6 <0
The p values were calculated using analysis of covariance or c2 test. Bold va
The concentration ranges for Hcy and folate were set according to Refs 26 an
HcyZ homocysteine; FolZ folate; MCIZmild cognitive impairment; CERAdementia with a crude OR of 4.56. After adjusting for
covariates, the OR was increased to 5.18 (pZ 0.001).
The intermediate hyperhomocysteinemia (>30 mmol/L)
diagnosed in 1.9% (17 subjects) of the participants had
much higher risk for dementia (adjusted ORZ 15.59,
pZ 0.007). Furthermore, low levels of serum folate
(<3.0 ng/mL) had an increased risk for dementia (crude
ORZ 3.68, pZ 0.039), but adjusted OR was not
significant. High folate levels (17.0 ng/mL) did not
show a protective effect. With respect to associations
with MCI, the high folate levels showed protective
effect against MCI (crude ORZ 0.63, pZ 0.045), but
the effect was not significant after adjusting for the
confounding factors (pZ 0.312). The Hcy levels were
not associated with the risk for MCI.
4. Discussion
The main outcome of this cross-sectional study was the
significant differences in serum Hcy, folate, and vitamin
B12 concentrations between dementia patients and
healthy controls. In addition, elevated Hcy and
decreased folate levels were correlated with a decreasem homocysteine and folate concentrations
Folate (ng/mL)
p Fol< 3.0 3.0 Fol< 17.0 17.0 Fol p
26 746 90
.001 72.6 5.0 71.1 5.2 70.9 5.0 0.314
.001 20/6 323/423 36/54 0.002
.815 7.6 4.6 7.2 5.1 8.7 5.4 0.028
.001 2.5 0.3 7.7 3.1 24.8 7.9 <0.001
.001 531.6 294.3 689.3 280.5 850.2 411.2 <0.001
.001 23.7 9.8 13.4 4.7 11.0 3.6 <0.001
.973 14 336 32 0.040
.001 4 49 3 0.020
.001 53.8 14.8 60.9 14.0 64.6 11.9 0.002
lues are p< 0.05.
d 27, respectively.
DZConsortium to Establish a Registry for Alzheimer’s Disease.
Table 3 Odds ratios and 95% confidence interval for dementia and mild cognitive impairment according to serum homo-
cysteine (mmol/L) and folate (ng/mL) concentrations
Models 15<Hcy 30 30<Hcy Folate< 3.0 17.0 Folate
Dementia
Unadjusted 4.56 (2.51e8.26) 7.91 (2.16e28.90) 3.68 (1.07e12.69) 0.40 (0.12e1.33)
Model 1 6.38 (2.44e16.72) 24.35 (3.70e160.20) 6.13 (1.02e36.64) 0.44 (0.10e1.94)
Model 2 5.18 (1.91e14.10) 15.59 (2.11e115.04) 2.34 (0.38e14.62) 0.77 (0.16e3.73)
MCI
Unadjusted 1.04 (0.74e1.47) 0.96 (0.32e2.88) 1.88 (0.78e4.54) 0.63 (0.39e0.99)
Model 1 0.89 (0.57e1.38) 0.48 (0.12e1.88) 2.13 (0.74e6.12) 0.77 (0.44e1.35)
Model 3 0.82 (0.52e1.30) 0.43 (0.11e1.73) 2.47 (0.80e7.63) 0.74 (0.42e1.32)
Model 1: adjusted for age, gender, and years of education. Model 2: adjusted for age, gender, years of education, vitamin B12, and folate (or
homocysteine).
The reference concentrations were Hcy 15 mmol/L and 3.0 ng/mL Folate< 17.0 ng/mL. Bold values are p< 0.05.
MCIZmild cognitive impairment; HcyZ homocysteine.
Dementia and serum levels of homocysteine and folate 21in cognitive functioning as measured by CERAD and
MMSE scores. Hcy concentrations higher than 15 mmol/
L increased the risk of dementia by 5.7 times the Hcy
level of 15 mmol/L or lower (adjusted ORZ 5.69; 95%
confidence interval: 2.13e15.22; p< 0.001).
In accordance with previous studies, our results showed
that serumHcy levels increasedwith age andwerehigher in
males than in females and that Hcy and folate levels are
associated with cognitive status or risk for dementia.6,8 A
similar study was reported from a prospective Kwangju
community survey,which showed that incident dementia is
strongly associated with lower folate and vitamin B12
concentrations and higher Hcy concentrations in Korean
elderly people.28 However, some studies observed no
relationship between Hcy levels and cognitive impair-
ment.9 Among community-dwelling elderly subjects aged
55 years and older from the population-based Rotterdam
study in the Netherlands, no relationship was found
betweenHcy levels and concurrent cognitive impairments,
as assessed by MMSE, or subsequent cognitive decline
over 2.7 years.29
The association between elevated Hcy levels and
dementia may be explained by several mechanisms,
including neurotoxic effect of Hcy. A number of
findings demonstrate that the central nervous system is
acutely sensitive to Hcy, probably because of its
stimulating effects on calcium influx and promotion of
glutamate excitotoxicity as well as its role in reactive
oxygen species-mediated insults.2 A recent animal
study showed that hyperhomocysteinemia could
increase beta amyloid production through the enhanced
expression of g-secretase complex and amyloid
precursor protein phosphorylation, causing memory
deficits that could be rescued by folate and vitamin B12
treatment30 suggesting a plausible link between Hcy
and the pathogenesis of AD. Although the generation
and toxicity of Hcy are not completely understood, it
might be beneficial to use Hcy as a biomarker for
cognitive decline.High Hcy has been correlated with decreased brain
volume. A recent clinical trial showed that the supple-
mentation of high-dose B vitamins to MCI patients for 2
years reduced Hcy levels and had beneficial effects on
brain shrinkage.31 An interesting observation was that B
vitamin treatment slowed the rate of brain atrophy and
memory decline only in the group with initial Hcy level
higher than 13 mmol/L (top quartile) but not in the group
with the initial Hcy level below 9.5 mmol/L (lowest
quartile). The results suggest that the treatment with
Hcy-lowering B vitamins could be an effective way of
delaying onset of dementia for those with moderate
hyperhomocysteinemia.
Numerous studies have shown that the elevated blood
Hcy is associated with impaired cognition and a higher
risk of dementia.5e8 In this study, we focused on
comparing the serum Hcy, folate, and vitamin B12 levels
in association with the risk for MCI or dementia. One
limitation of this study is that we did not include the
analyses of other confounding factors that might influ-
ence the incidence of dementia, such as alcohol
consumption, smoking, and exercise habits. Although
we observed weak association between drinking,
smoking, and exercise habits and prevalence of MCI or
dementia, some of the data were not reliable in that they
were obtained from self-reports of the patients and some
of the data were not available. Another limitation of this
study is that this is a cross-sectional study that could not
address causal relation between Hcy level and cognitive
impairment. Despite these limitations, the association
between Hcy and cognitive decline is consistent with
previously published data. Further follow-up studies are
needed to examine whether serum Hcy level could be
used as a peripheral biomarker for cognitive decline and
onset of dementia.
In conclusion, the apparently strong association of
high Hcy levels with the risk of dementia and cognitive
impairment suggests that hyperhomocysteinemia and
low folate levels may serve as independent risk factors
22 J.H. Song et alfor dementia in Koreans. Further efforts are needed to
identify at-risk elderly population and targets for early
intervention to reduce the risk of late-life dementia.
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